Dynavax gets $50mm in special funding from Symphony
Private equity firm Symphony Capital has formed financing and clinical development vehicle Symphony Dynamo and funded the new company with $50mm to continue development on Dynavax's cancer, hepatitis B and hepatitis C programs.
- Antisense, Oligonucleotides
- Large Molecule
- Special-Purpose Financing Vehicle
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com